U.S. Department of Labor

Office of Inspector General Washington, DC. 20210



February 12, 2021

MEMORANDUM FOR:

CHRISTOPHER GODFREY Director Office of Workers' Compensation Programs

Caroly R. Hanty

FROM:

CAROLYN HANTZ Assistant Inspector General for Audit

SUBJECT:

Audit of FECA Pharmaceutical Spending, Project No. 03-P20-003-04-431

Please be advised the Office of Inspector General (OIG) is initiating an audit of pharmaceutical spending in the Federal Employees' Compensation Act (FECA) program. Our focus will be on identifying the major factors influencing pharmaceutical spending in the FECA program, including identifying the impact from the COVID-19 pandemic and determining whether the Office of Workers' Compensation Programs (OWCP) effectively manages pharmaceutical spending. The OIG has contracted with Harper, Rains, Knight & Company (HRK) to perform this audit.

We will contact your audit liaison to schedule a meeting to discuss the audit's objective, scope, and methodology.

Immediately after our meeting, HRK plans to begin work and would appreciate your notifying appropriate agency officials of our plans. If you have questions, please contact Stephen Sovich, Audit Manager, at (215) 446-3723 or <u>sovich.stephen@oig.dol.gov</u>.

cc: Jatin Wahi Audit Liaison, OWCP

> Antonio Rios Director, Division of Federal Employees', Longshore and Harbor Workers' Compensation